We are live on ! Find out more
JHC

Jones Hill Capital Portfolio holdings

AUM $589M Turnover 70.83%
This Fund
S&P 500
This Quarter Est. Return
-13.76%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$589M
AUM Growth
+$119M
Cap. Flow
+$204M
Cap. Flow %
34.65%
Top 10 Hldgs %
68.09%
Holding
48
New
19
Increased
9
Reduced
5
Closed
15
Avg Time Held
0.2 years
Top 10 Avg Time Held
0.1 years
Top 20 Avg Time Held
0.2 years

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$11.7B
$70.3M 11.93%
1,171,859
-259,731
-18% -$16.4M
2026 Q1
2 quarters
BCRX icon
2
BioCryst Pharmaceuticals
BCRX
$1.86B
$59M 10.01%
+7,083,300
New +$66.7M
2026 Q3
0 quarters
TVTX icon
3
Travere Therapeutics
TVTX
$4.51B
$56.5M 9.59%
+959,634
New +$58.6M
2026 Q3
0 quarters
SUPN icon
4
Supernus
SUPN
$5.94B
$54.7M 9.29%
+1,526,685
New +$57.6M
2026 Q3
0 quarters
PHVS icon
5
Pharvaris
PHVS
$2.21B
$31.3M 5.32%
987,637
+309,758
+46% +$10.8M
2026 Q1
2 quarters
CELC icon
6
Celcuity
CELC
$2.61B
$30.4M 5.17%
+382,901
New +$34.8M
2026 Q3
0 quarters
IONS icon
7
Ionis Pharmaceuticals
IONS
$4.43B
$26.8M 4.55%
+599,826
New +$34.1M
2026 Q3
0 quarters
SUPN icon
8
DELISTED
Supernus Pharmaceuticals
SUPN
$25.9M 4.4%
+601,685
New +$27.4M
2026 Q3
0 quarters
NUVB icon
9
Nuvation Bio
NUVB
$1.34B
$25.1M 4.26%
+4,486,986
New +$28.2M
2026 Q3
0 quarters
VERA icon
10
Vera Therapeutics
VERA
$1.84B
$21.1M 3.57%
+652,218
New +$22.8M
2026 Q3
0 quarters
TRVI icon
11
Trevi Therapeutics
TRVI
$1.9B
$20.7M 3.52%
1,447,156
+107,944
+8% +$1.86M
2026 Q1
2 quarters
BCAX icon
12
Bicara Therapeutics
BCAX
$560M
$19.8M 3.36%
1,064,233
+171,612
+19% +$4.3M
2026 Q1
2 quarters
RLMD icon
13
Relmada Therapeutics
RLMD
$280M
$19.7M 3.35%
5,237,628
+1,582,553
+43% +$7.76M
2026 Q1
2 quarters
ABVX icon
14
Abivax
ABVX
$6.41B
$14.1M 2.4%
+142,558
New +$17.2M
2026 Q3
0 quarters
ACRS icon
15
Aclaris Therapeutics
ACRS
$546M
$13.2M 2.24%
2,504,651
+745,159
+42% +$4.25M
2026 Q2
1 quarter
INSM icon
16
Insmed
INSM
$31B
$12.2M 2.06%
106,528
-15,847
-13% -$1.87M
2026 Q2
1 quarter
NBIX icon
17
Neurocrine Biosciences
NBIX
$15.2B
$11.8M 2.01%
+83,426
New +$13.4M
2026 Q3
0 quarters
IMCR icon
18
Immunocore
IMCR
$1.36B
$11.6M 1.98%
384,278
-128,578
-25% -$4.37M
2026 Q2
1 quarter
ERAS icon
19
Erasca
ERAS
$4.78B
$8.94M 1.52%
+610,118
New +$10.7M
2026 Q3
0 quarters
CAPR icon
20
Capricor Therapeutics
CAPR
$441M
$8.45M 1.43%
892,532
+471,781
+112% +$5.23M
2026 Q1
2 quarters
DNTH icon
21
Dianthus Therapeutics
DNTH
$4.76B
$7.05M 1.2%
80,017
+22,917
+40% +$2.38M
2026 Q2
1 quarter
NGNE icon
22
Neurogene
NGNE
$459M
$6.06M 1.03%
+217,700
New +$7.76M
2026 Q3
0 quarters
CRBP icon
23
Corbus Pharmaceuticals
CRBP
$42.4M
$6.05M 1.03%
886,428
+232,856
+36% +$2.15M
2026 Q2
1 quarter
TNXP icon
24
Tonix Pharmaceuticals
TNXP
$46.2M
$5.49M 0.93%
563,739
-61,689
-10% -$728K
2026 Q1
2 quarters
SGMT icon
25
Sagimet Biosciences
SGMT
$648M
$4.97M 0.84%
+502,587
New +$4.62M
2026 Q3
0 quarters

Similar funds

Jones Hill Capital's Q3 2026 Portfolio in Review

As of Q3 2026, Jones Hill Capital held 48 positions worth $589M, up 25% from $470M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Jones Hill Capital deployed $204M of net new capital in Q3 2026, opening 19 new positions and adding to 9 existing holdings. Its largest new stake was BioCryst Pharmaceuticals: 7,083,300 shares worth $59M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $16.4M trimmed.

  • Jones Hill Capital's largest Q3 2026 buy was BioCryst Pharmaceuticals: 7,083,300 shares worth $59M.
  • Jones Hill Capital added most to Pharvaris in Q3 2026, an estimated $10.8M increase.
  • Jones Hill Capital's biggest Q3 2026 reduction was BioMarin Pharmaceuticals, cutting an estimated $16.4M.
  • Jones Hill Capital fully exited Gilead Sciences in Q3 2026, selling an estimated $43.3M.
  • Jones Hill Capital's ten largest holdings make up 68% of its $589M portfolio in Q3 2026.
  • Jones Hill Capital opened 19 new positions and closed 15 in Q3 2026.
  • Jones Hill Capital's portfolio value rose 25% quarter-over-quarter to $589M.

Based on Jones Hill Capital's 13F filing for Q3 2026, filed 13 Nov 2026.